All News

The Board of Physiomics Plc (AIM: PYC), a UK-based systems biology company, today announces the financial results for the six months ended 31 December 2011. Physiomics Plc is a computational systems biology services company, applying simulations supporting pharmaceutical decision making throughout the entire drug discovery process, particularly for cancer therapies. Read more...

Physiomics plc is pleased to announce that it has signed a new agreement with a major global pharmaceutical company. Under the agreement, Physiomics will determine the optimal dosing and timing of a new compound currently under development by this new client, in combination with irradiation therapy. Read more...

Physiomics plc (AIM: PYC), the Oxford, UK-based systems biology company, is pleased to announce its intention to increase the scope of its offering through the development of a new modelling service to predict the cardiac toxicity of drugs.  The Directors believe that this new service will be of particular interest to biotechnology companies looking to streamline their drug discovery programmes and improve the success rates...

  The below excerpt has been taken from InSphero’s latest newsletter, 'Upgrade Your Cell-Based Assays to 3D', discussing the collaboration between InSphero and Physiomics plc. Customer case study: 3D microtissue growth and drug response – virtual and in vitro models InSphero’s customer Physiomics plc develops computational systems-biology models to predict and understand cancer drug efficacy from pre-clinical research to clinical development. The Oxford (UK)-based company has created detailed...